Abstract
The AA protein is a major improvement in allergy medications. It utilizes advanced technologies such as gene therapy to reach its goal. It is created in the body, via a retrovirus. It stops allergic reactions at the source, so they don’t happen in the first place. It does this by stopping the production of anaphylatoxins, fragments released in the complement system, that bind to basophil, and mast cells, which release histamine, causing allergic symptoms. For reactions genetically related, it will target genes inside the chromosomes, which play a part in causing the allergy, and turn them off. In this way it will act as a regulator protein.